A monoclonal radioimmunoassay (RIA) was developed for detection of dengue virus in infected cell culture fluids and blood samples from dengue patients. Antibodies used to construct the R1A were selected on the basis of high binding avidity, the demonstration of synergism in competitive binding assays and empirical trials with different antibody combinations. Optimal binding of all four dengue virus serotypes was achieved by use of a flavivirus group-reactive and a dengue virus complex-reactive antibody attached to a solid-phase support and a single flavivirus subgroup-reactive antibody as radiolabelled probe. A 'simultaneous sandwich' format and prolonged (18 h) incubation at 37 °C yielded optimal results. The limit of sensitivity of the RIA for detection of dengue type 2 virus was 2.7 log10 mosquito 50 ~o infectious doses (MIDs0). The assay was tenfold more sensitive for dengue type 2 than for dengue types 1 and 3 viruses and 100-fold more sensitive than for dengue type 4 virus. Specificity, assessed using over 500 disease control human sera, was increased by addition of monoclonal anti-tetanus blocking antibodies, resulting in a false positive rate of only 0.2%. Heterologous dengue virus antibodies were shown to inhibit the RIA in assays • • 4.2 performed with artificial immune complexes. Acute phase human sera containing 10 to 10 7.6 MIDso but no detectable antigen by RIA, were also shown to inhibit binding of the homologous dengue virus serotype; this effect was attributed to heterologous antibody from a prior infection. Among 116 viraemic sera from dengue patients, the RIA was positive in 43 to 47 % of patients with dengue type 1, 2 or 3 infections but in only 10% of the dengue type 4 cases. Virus was more frequently detected in cases of primary infection (54%) than in cases of superinfection (16%). Despite the limitations imposed by immunological interference, the antigen capture RIA appears useful as a rapid diagnostic technique for dengue surveillance•
INTRODUCTION
Dengue fever is an acute, self-limiting, mosquito-borne, flavivirus infection characterized by fever, headache, arthralgia and rash and is caused by four serotypes of dengue virus (designated dengue types 1, 2, 3 and 4). Cross-protection between serotypes is incomplete and transient, and sequential infections occur frequently in endemic areas. A severe, occasionally fatal, form, dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS), is an immunopathological disease occurring principally in children who sustain a second infection with a heterologous serotype (Halstead, 1980) . Dengue and DHF/DSS are the most important arthropod-borne viral 
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infections of humans. Epidemics affecting as many as 1 million people occur at frequent intervals in tropical areas of the world.
Specific laboratory diagnosis of dengue is an essential component of public health programmes, which emphasize surveillance and deployment of mosquito control. The most sensitive technique presently available is virus isolation from serum obtained during the acute phase of illness. Specimens are inoculated either into mosquito cell cultures or intrathoracically into live mosquitoes and virus is detected by immunofluorescence after an appropriate incubation period (usually 7 to 14 days) (Rosen & Gubler, 1974) . Since patients with dengue circulate virus in the blood for 3 to 7 days at sufficient titre to infect mosquito vectors (Gubler et al., 1981) , direct detection of viral antigen by immunoassay should be feasible and would provide a means of rapid, early diagnosis. Despite numerous attempts by several laboratories, this approach has not been successful. A recognized theoretical obstacle to antigen detection in serum is the presence of heterologous antibodies, particularly in cases of sequential infection.
We have developed a multisite monoclonal radioimmunoassay (RIA) with high sensitivity for dengue viruses grown in cell culture. The RIA utilizes antibodies directed against dengue complex-reactive and flavivirus subgroup-and group-reactive epitopes, permitting detection of all four dengue virus serotypes. These antibodies demonstrated high avidity and exhibited synergistic binding in competitive binding assays. In the present report, we describe methods used to construct the RIA, optimal conditions for antigen detection, sensitivity and specificity of the assay, and results of tests performed on acute phase, viraemic sera from dengue patients. Virus was detected more frequently in sera from persons with primary dengue infections than in those with superinfections. Heterologous antibodies were implicated in blocking of virus detection in the latter cases.
METHODS
Viruses. Dengue type 2 virus strain PR 152 (Puerto Rico, 1969) , used to construct RIAs, was grown in C6/36 Aedes albopietus cells. RIAs were performed with cell culture supernatant fluid or partially purified virus. Partial purification was achieved by precipitation of supernatant fluid from ten 175 cm 2 flasks of infected C6/36 cells with 7% polyethylene glycol (PEG 8000; Fisher Scientific, Pittsburgh, Pa., U.S.A.) at 4 °C for 16 h and centrifugation of the precipitate dissolved in TNE buffer (Trent & Grant, 1980) for 4 h at 280000 g. The resulting pellet was resuspended in 1-~0 ml Tris buffer pH 8.0 and stored at -70 °C until used.
Antibodies. Monoclonal antibodies (mouse ascitic fluids) were developed and prepared at the Walter Reed Army Institute of Research (Gentry et al., 1982) . Selected characteristics of these antibodies are shown in Table 1 . Antibodies were purified by ammonium sulphate precipitation and affinity chromatography with Protein ASepharose (Ey et aL, 1978) . Antibodies were shown to be 95 to 98% pure by SDS-PAGE using 10% polyacrylamide resolving gels. Antibodies were labelled with ~25I to a specific activity of 8 to 12 ktCi/~tg by the iodogen method (Fraker & Speck, 1978) and stored in foetal bovine serum (FBS) at 4 °C.
Clinical samples. Sera from confirmed dengue patients in Indonesia, Mexico, Puerto Rico and the Dominican Republic had been found to contain virus by inoculation of Toxorhynchites mosquitoes or of mosquito cell cultures and were stored at -70 °C until tested by RIA. Titrations of infectious virus were performed by intrathoracic inoculation of Toxorhynchites amboinensis mosquitoes (Rosen & Gubler, 1974) and are expressed as log10 mosquito 50~ infectious doses (log~0 MIDs0) per 100 Ixl. Antibody determinations by the haemagglutination-inhibition (HI) test (Clarke & Casals, 1958) were used to distinguish primary dengue from superinfection, according to criteria previously published (Gubler et al., 1981) .
R1As. The'simultaneous sandwich' RIA technique used to measure dengue virus has been previously described for detection of hepatitis B surface antigen (HBsAg) (Wands et al., 198 l) and yellow fever virus (Monath et al., 1986) . Polystyrene beads, outer diameter 0.64 cm (Precision Plastic Ball Co., Chicago, II1., U.S.A.) were coated with monoclonal ascites fluid diluted in phosphate-buffered saline pH 7-2 for 16 h at room temperature with continuous mixing, and were then washed extensively with distilled H20. Virus, diluted in FBS, was added in 100 ktl volumes tO duplicate wells of 25-well plastic reaction trays (Centocor, Malvern, Pa., U.S.A.); antibody-coated beads were placed in each well, followed by 100 ktl of radiolabelled detecting antibody containing 150000 c.p.m. After incubation under optimal conditions, beads were washed using a mechanical device (Pentawash; Abbott Laboratories, North Chicago, I11., U.S.A.) and bound radioactivity was measured in a gamma well counter. Results are expressed as the signal/noise (S/N) ratio, calculated as mean c.p.m, of ~25I-labelled antibody bound divided by the mean c.p.m, of negative control serum (FBS for cell culture-propagated virus, normal human serum for clinical samples). Henchal et al. (1985) and D. S. Burke et al. (personal communication, 1985) . t HI, haemagglutination inhibition; N, neutralization.
:~ Mixed isotypes (see previous report by Gentry et al., 1982) . § Reactive with dengue type 1 to 4 viruses plus one or more heterologous flaviviruses.
Antibody avidity. Relative avidities of the monoclonal antibodies used to construct RIAs were assessed by a modification of previously published methods (Frankel & Gerhard, 1979; Schlesinger et al., 1984) . Polystyrene beads were coated with partially purified dengue type 2 virus; a dilution (generally 1 : 50) of partially purified virus was used, which gave maximum binding as determined by preliminary titration. Coated beads were added to 200 ~tl of purified antibodies at various concentrations (from 0.005 to 10 ~tg/200 ~1) diluted in FBS. After incubation (4 h at 37 °C), the beads were washed and then exposed to 125i.labelled Protein A (Amersham; sp. act. 39 ~tCi/txg) at 150000 c.p.m, in 200 ~tl for 1 h at 37 °C.
In other experiments, avidity of radiolabelled monoclonal antibodies was assessed by determining binding to beads coated with partially purified dengue type 2 virus. Labelled antibodies (sp. act. 8 to 12 ~tCi/~tg) containing 150000 c.p.m./100 ~tl were added to beads and binding was determined after 4 h incubation at 37 °C.
Competitive binding assays. These assays were performed to determine whether antibodies inhibited or augmented binding of other antibodies to dengue virus. To beads coated with partially purified dengue type 2 virus, we added, in sequence, unlabelled purified competitor antibody (containing 2 ~tg in 100 ~tl) and radiolabelled antibody (150000 c.p.m, in 100 ~tl). Controls included homologous unlabelled antibody (positive control) and FBS (negative control). Percentage competition (or augmentation) was calculated with reference to the negative control.
Blocking antibody. To reduce non-specific binding of different concentrations of radiolabelled dengue monoclonal antibody probe in tests with human sera, a mixture of IgG 1 and IgG2a anti-tetanus toxoid monoclonal antibodies (B2TT) (Zurawski et al., 1980) was added at a concentration of 200 ~tg/ml.
RESULTS

Avidity
Avidity was estimated in two ways. First, binding of unlabelled purified antibody to beads coated with partially purified dengue type 2 virus was measured by addition of 125I-labelled Protein A (Fig. 1) . Four antibodies showed relatively high binding avidities, including three antibodies (4G2, 9D12 and 1B7) directed against complex-or group-reactive epitopes. All but one (1B7) of these monoclonal antibodies were produced using the myeloma protein-secreting P3-X63-Ag8 cell line.
Since Protein A has different binding affinities for different IgG subclasses, a modification of the avidity assay was also used to assess binding of various concentrations of radiolabelled monoclonal antibodies (sp. act. 8 to 12 ~tCiAtg) to dengue type 2 virus directly coated on polystyrene beads (Fig. 2) . Among the seven antibodies directed against complex-or groupreactive antigenic sites, five (1B7, 5B2, 9D12, 13G9, 4G2) demonstrated high binding affinities; the highest affinities were obtained with 1B7, 9D12, and 4G2.
Competitive binding assays
Antibodies used for capture and detection of virus should ideally not be directed against the same or closely expressed (competing) epitopes. Conversely, there should be a theoretical Relative avidities of radiolabelled dengue type 2 monoclonal antibodies. Partially purified dengue type 2 virus coated on polystyrene beads was incubated with labelled antibodies; beads were washed and bound radioactivity was determined. Note that some antibodies which showed very low binding in the assay described in Fig. 1 demonstrated high reactivities in this assay (e.g. 3H5, 5B2), presumably reflecting low binding of these antibodies to Protein A.
advantage in the use of antibody pairs that exhibit synergistic binding, a phenomenon previously described for dengue (Henchal et al., 1985) and other flaviviruses (Heinz et al., 1984) .
The results of competitive binding assays (Table 2 ) illustrate the phenomenon of synergistic binding. For example, binding of radiolabelled 1 B7 is augmented in the presence of antibodies 5B2, 9D12 or 4G2. Among the dengue complex-and group-reactive monoclonal antibodies, three antibodies (1B7, 9D12 and 4G2) demonstrated synergism in at least one direction. Antibodies 5B2 and 1B7 showed reciprocal augmentation of binding, but 5B2 and 4G2 showed reciprocal competition. Thus, the use of a combination of three antibodies (either 1B7-9D12-4G2 or 1B7-9D12-5B2) was indicated for construction of a sensitive diagnostic RIA.
Since antigenic variation has been demonstrated between strains of dengue type 2 virus by RIAs (T. P. Monath & J. R. Wands, unpublished observations) it was of interest to determine whether the antibody interactions measured in competitive binding assays were consistent for an array of different dengue type 2 virus strains. Although quantitative differences in binding were observed in assays with six dengue type 2 virus strains (Table 3) , the direction of antibody interaction (competition or augmentation) remained constant.
Design of antigen capture RIA
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capture and detection. Certain results were predicted; antibodies that demonstrated competition in competitive binding assays showed little binding in simultaneous sandwich RIAs (e.g. 5B2-4G2). Other results were unexpected; for example, 1B7 used on the solid phase was inefficient for capture of virus but highly efficient as a-125I-labelled probe. Optimal binding was achieved by the use of two antibodies on the solid-phase support (4G2 and 9D 12) and a single radiolabelled antibody probe (1B7). These antibodies showed the highest avidities among the flavivirus subgroup-and group-reactive antibodies (Fig. 1, 2 ) and synergism in competitive binding assays (Tables 2 and 3) .
Conditions for virus binding
The optimal concentrations of 4G2 and 9D12 capture antibodies were determined in RIAs with different dilutions of each antibody. Maximal virus binding was achieved at a 1:500 dilution of both antibodies (data not shown).
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t Percent binding was relative to negative control (FBS in place of competing antibody).
dengue type 2 virus were tested in simultaneous sandwich RIAs at four temperatures (4, 22, 37 and 45 °C) for 1, 2, 4 or 18 h (Fig. 4) . Optimal binding was achieved by incubation for 18 h at 37 °C.
Sensitivity
The limit of detection of dengue type 2 virus in infected cell culture fluid was found to be approximately 2.7 log10 MIDso/100 tll (Fig. 5) . Sensitivity of the assay was not significantly affected by dilution of the virus in freshly frozen normal human serum. To determine the relative sensitivity of the RIA for other dengue serotypes, two virus strains of each serotype which had undergone a single passage in Toxorhynchites mosquitoes were tested at serial dilutions (Fig. 6 ).
The assay was approximately tenfold more sensitive for dengue type 2 virus than for dengue type 1 and 3 viruses and 100-fold more sensitive than for dengue type 4 virus.
Specificity
Sera from patients with liver disease, including viral hepatitis, at Massachusetts General Hospital were tested in RIA with and without inclusion of B2TT blocking antibody. Of 272 Human sera containing dengue virus were passed once by intrathoracic inoculation of Toxorhynchites mosquitoes and the resulting seed pool was titrated in the same system. Virus strains (origin) used were: dengue type 1,809 (Indonesia) and 892 (Indonesia); dengue type 2, 8738 (Indonesia) and 7761 (Indonesia); dengue type 3, 831 (Indonesia) and 2958 (Indonesia); dengue type 4, 203553 (Mexico) and 65406 (Puerto Rico).
disease control sera tested without B2TT, six (2.2%) were positive (S/N > 2.0) in the dengue RIA (Fig. 7) . These plus 248 other control sera were tested with addition of B2TT to the radiolabelled probe; only one serum was found positive, giving a false positive rate of 1/520 or 0.2%.
Effect of heterologous antibodies
Clinical infections with dengue virus frequently occur in individuals who have previously been exposed to one or more heterologous dengue serotypes. Such individuals not only have preexisting dengue antibodies in their sera, but also develop brisk anamnestic antibody responses, especially to dengue group-reactive determinants and determinants specific to the original infecting serotype. These antibodies may complex with virus and potentially interfere with its detectability in RIA.
To investigate this phenomenon, we prepared artificial immune complexes by incubating (1 h, 37 °C) 50 ~tl of dengue type 2 virus (containing sufficient virus to bind 10000 c.p.m, in the RIA described above) with an equal volume of serial fivefold dilutions of polyclonal antibodies. The antibodies used were pooled human convalescent phase sera from three patients who had sustained primary infections with either dengue type 1, 2, 3 or 4 virus; sera incorporated in the pools had HI antibody titres to the infecting serotype of 80 to 320. Mixtures were tested by RIA. Antibody pools inhibited binding of dengue type 2 virus by 90 to 95 % when tested undiluted; endpoints of inhibition corresponded to the HI antibody titres (data not shown).
Five sera obtained from individuals during the acute phase of infection with dengue type 1, 2 or 3 viruses (Table 4) were tested for their ability to inhibit binding of the homologous dengue serotype. These sera, which contained 4.2 to 7.6 log lo MIDso/100 gl of infectious virus had been found negative in antigen capture RIA. The inhibition assay design, similar to that used to investigate artificial immune complexes, is given in the legend to Fig. 8 . Three acute phase, viraemic sera (718,731 and 8738) showed strong inhibition at dilutions up to 1:125. These sera Table 4 ; these sera had been tested and found negative in antigen capture RIA. Viraemic sera were mixed with an equal volume (50 ~tl) of dengue virus of the same serotype, the mixtures incubated for 1 h at 37 °C, and then tested in 'simultaneous sandwich' RIA. Three sera (718, 731, 8738) inhibited binding of homologous virus; these sera were from patients sustaining dengue superinfections. were from patients who had serological responses indicating superinfection. Two sera (809, 831) showed minimal inhibition; these sera contained no detectable HI antibody and probably represented individuals who had sustained primary dengue infections. . Relationship between S/N ratio in RIA and infectivity titre, using viraemic human sera from patients sustaining primary (O) and superinfections ((3) with dengue type 1 (a), dengue type 2 (b), dengue type 3 (c) or dengue type 4 (d). Volumes of sera used in RIA varied from 10 to 200 ~tl due to limited quantities available; infectivity titre is thus expressed as the absolute value contained in the volume tested. 
Viraemic human sera
A total of 116 viraemic sera from dengue patients was tested by RIA. The results are summarized by infecting serotype and whether the serological pattern indicated primary or superinfection (Table 5 ). RIA detected virus in sera from 43 to 47 ~ of patients with dengue type 1, 2 and 3 infections, but in only 10 ~o of the dengue type 4 cases. Virus was more frequently detected in cases of primary infection (54~) than in cases of superinfection (16~).
The relationships between RIA S/N ratios and infectious virus titres in sera are shown in Fig.  9 . In general, sera containing very small amounts of infectious virus (less than 3 log~o MID5o)
were negative or weakly positive in RIA. Patients with primary dengue type 1 infections showed a correlation between infectivity titrations and S/N, but more variation was observed with the other serotypes. Several sera from dengue type 2 and 3 cases had high S/N values but relatively low titres of infectious virus. These sera contained high concentrations of non-infectious antigen, probably corresponding to the slowly sedimenting haemagglutinating particles described by Brandt et al. (1970) . More difficult to explain are the cases having high infectious virus titres but low RIA signals.
DISCUSSION
Three sources of information were used to construct an RIA for dengue virus: (i) relative binding avidities of monoclonal antibodies, (ii) competitive binding assays and (iii) empirical trials with different antibody combinations. Since the objective was to measure all four dengue virus serotypes by means of a single assay, it was necessary to utilize monoclonal antibodies against dengue complex-reactive or flavivirus group-reactive determinants. Among the latter, three antibodies (4G2, 9D12 and 1B7) were found to have high relative binding avidities. These three antibodies, as well as 5B2, showed the phenomenon of augmentation in competitive binding assays (Tables 2 and 3 ). Thus, for example, unlabelled 5B2, 9D12 and 4G2 antibodies increased binding of radiolabelled 1 B7 by two-to fourfold. Similar results have been reported for dengue virus monoclonal antibodies by Henchal et al. (1985) and for tick-borne encephalitis virus by Heinz et al. (1984) . Augmentation has been postulated to be due either to antibodyinduced conformational change in antigenic structures or to antibody-antibody synergistic interactions. Whatever the mechanism, the demonstration of augmented binding appears to be useful in the selection of antibody combinations for sensitive antigen detection immunoassays.
Based on avidity and competitive binding assays, as well as empirical trials of various antibody combinations, we constructed an RIA which utilized two non-competing monoclonal antibodies (4G2, 9D12) for antigen capture on the solid phase and a single radiolabeUed antibody probe (1B7). The sensitivity of the assay was highest for dengue type 2 virus and was capable of detecting as little as 2.7 log10 MID50/100 p.1. Sensitivity for dengue type 4 virus was approximately 100-fold lower, perhaps because of the lower binding affinity of the 9D12 antibody for this virus. Henchal et al. (1985) reported that 9D12 is subcomplex-specific (reacting only with dengue types 1, 2, 3) but D. S. Burke (personal communication) found that 9D12 bound dengue type 4 at a lower level than the other serotypes.
In the development of RIAs for antigen detection, detailed studies are required to define optimal conditions, including time and temperature of incubation and concentration of capture antibodies. Maximal binding of dengue virus was observed under conditions involving 18 h incubation at 37 °C. A similar RIA for detection of another flavivirus, yellow fever virus (Monath et al., 1986) , produced highest binding at 45 °C, illustrating the need to specify optimal conditions for each virus-antibody system. Specificity of the dengue RIA was significantly increased by incorporating a mixture of irrelevant (anti-tetanus) monoclonal antibodies of the same isotypes (IgG1 and IgG2a) as the dengue antibodies used for capture and detection. The mechanism of action of blocking antibody presumably involves competition with factors present in some sera, possibly including anti-mouse IgG, which non-specifically bind to antibodies used in the RIA.
Despite considerable effort by a number of investigators, direct detection of dengue viruses in blood has proved to be extremely difficult. Underlying this difficulty is the presence of antibody in acute phase sera of persons sustaining dengue virus superinfections. The latter are the rule rather than the exception in many parts of the world. In a prospective study of children between 1 and 10 years of age in Thailand, 35% of those infected in 1980 had had a prior exposure to a heterologous dengue serotype (Sangkawibha et al., 1984) . In endemic areas, the frequency of superinfection increases dramatically with age. Individuals undergoing superinfection have preexisting antibodies directed against type-specific determinants of the original infecting serotype(s) and against dengue complex-and group-reactive epitopes. Exposure to a new, heterologous virus results in a rapid anamnestic antibody response against antigens present in the original serotype(s) (Halstead et al., 1983) . Since the monoclonal antibodies used to construct the antigen capture RIA are also directed against complex-and group-reactive epitopes, high titres of antibody and immune complexes present in viraemic serum may compete with or block binding of viral antigen. Immune complexes have been detected in sera from DHF patients undergoing secondary infections (Theofilopoulos et al., 1976) .
The role of pre-existing antibody in blocking virus detection is illustrated by the results of RIAs on clinical samples. Sera from individuals with superinfections containing up to 7.6 lOglo units of dengue virus were found negative by RIA; when mixed with a suspension of dengue virus, such sera effectively blocked detection by RIA. This effect was not evident with sera from patients undergoing primary infections or with normal human sera.
The presence of antibody and immune complexes represents a major obstacle to practical application and use of antigen detection immunoassays for rapid diagnosis of dengue. Techniques for separation and specific measurement of dengue antigen from immune complexes have not been developed. Since immune complexes exist in marked antibody excess, techniques directed at measuring changes in antibody titre after immune complex dissociation are unlikely to be successful. Development of high affinity monoclonal antibodies against typespecific determinants offers a promising approach, since acute phase sera contain interfering antibodies directed predominantly against complex-and group-reactive sites. None of the three dengue type 2-specific antibodies we examined provided a sensitive RIA, despite the high avidity of one of them (Fig. 1) . Ultimately, nucleic acid hybridization probes may allow detection of dengue viral RNA in clinical samples without interference from immunological phenomena. Despite its limitations, the immunoassay described in this paper may be applicable to surveillance and rapid diagnosis, especially where background immunity is absent or low (e.g. in the United States, in military groups or in childhood populations in areas prone to periodic epidemics). In our study, nearly 60~ of sera from all patients with primary infections were positive by RIA.
